Company · CIK 0001438533 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Travere Therapeutics, Inc. · TVTX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 SForm 4 → | Sep 17, 9:35 pm EDT | William E. RoteChief Research Officer | 209,048 | $62.83 | $13,135,397 | 98,197 | −68.0% | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:35 pm EDT | William E. RoteChief Research Officer | 191,500 | $21.40 | $4,099,050 | 211,047 | — | 10b5-1 |
| Sep 15, 2026 SForm 4 → | Sep 17, 9:35 pm EDT | Peter HeermaEVP, CHIEF COMMERCIAL OFFICER | 283,189 | $63.06 | $17,857,830 | 117,066 | −70.8% | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:35 pm EDT | Peter HeermaEVP, CHIEF COMMERCIAL OFFICER | 258,189 | $15.69 | $4,050,088 | 125,348 | — | 10b5-1 |
| Sep 15, 2026 SForm 4 → | Sep 17, 9:33 pm EDT | Jula InrigEVP, Head of R&D & CMO | 44,674 | $62.34 | $2,785,021 | 100,491 | −30.8% | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:33 pm EDT | Jula InrigEVP, Head of R&D & CMO | 32,395 | $8.93 | $289,287 | 145,165 | — | 10b5-1 |
| Sep 15, 2026 SForm 4 → | Sep 17, 9:32 pm EDT | Elizabeth E ReedChief Legal Officer and GC | 37,500 | $62.34 | $2,337,695 | 105,389 | −26.2% | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:32 pm EDT | Elizabeth E ReedChief Legal Officer and GC | 37,500 | $15.46 | $579,750 | 142,889 | — | 10b5-1 |
| Sep 15, 2026 SForm 4 → | Sep 17, 9:31 pm EDT | Eric M DubeCHIEF EXECUTIVE OFFICER, Director | 400,000 | $63.48 | $25,390,729 | 432,886 | −48.0% | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:31 pm EDT | Eric M DubeCHIEF EXECUTIVE OFFICER, Director | 400,000 | $23.34 | $9,336,000 | 541,379 | — | 10b5-1 |
| Sep 15, 2026 SForm 4 → | Sep 17, 9:30 pm EDT | Christopher R. ClineCHIEF FINANCIAL OFFICER | 50,508 | $62.34 | $3,148,544 | 87,508 | −36.6% | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:30 pm EDT | Christopher R. ClineCHIEF FINANCIAL OFFICER | 20,000 | $17.44 | $348,800 | 138,016 | — | 10b5-1 |
| Sep 15, 2026 SForm 4 → | Sep 17, 9:29 pm EDT | Sandra CalvinSVP, CHIEF ACCOUNTING OFFICER | 5,375 | $62.33 | $335,005 | 42,353 | −11.3% | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:29 pm EDT | Sandra CalvinSVP, CHIEF ACCOUNTING OFFICER | 5,375 | $24.19 | $129,998 | 47,728 | — | 10b5-1 |
| Sep 10, 2026 SForm 4 → | Sep 11, 4:05 pm EDT | Jeffrey A MecklerDirector | 20,000 | $67.31 | $1,346,106 | 91,500 | −17.9% | 10b5-1 |
| Sep 10, 2026 MForm 4 → | Sep 11, 4:05 pm EDT | Jeffrey A MecklerDirector | 20,000 | $21.98 | $439,600 | 111,500 | — | 10b5-1 |
| Sep 2, 2026 SForm 4 → | Sep 3, 4:05 pm EDT | Christopher R. ClineCHIEF FINANCIAL OFFICER | 642 | $66.37 | $42,610 | 118,016 | −0.54% | |
| Aug 17, 2026 SForm 4 → | Aug 19, 4:05 pm EDT | Gary A LyonsDirector | 10,000 | $63.28 | $632,846 | 61,500 | −14.0% | 10b5-1 |
| Aug 17, 2026 MForm 4 → | Aug 19, 4:05 pm EDT | Gary A LyonsDirector | 10,000 | $17.44 | $174,400 | 66,500 | — | 10b5-1 |
| Jun 22, 2026 GForm 4 → | Jun 22, 4:37 pm EDT | Jula InrigCHIEF MEDICAL OFFICER | 468 | — | — | 112,770 | — | |
| Jun 12, 2026 SForm 4 → | Jun 16, 4:46 pm EDT | Timothy CoughlinDirector | 10,000 | $50.07 | $500,747 | 56,250 | −15.1% | 10b5-1 |
| Jun 12, 2026 MForm 4 → | Jun 16, 4:46 pm EDT | Timothy CoughlinDirector | 10,000 | $26.52 | $265,200 | 66,250 | — | 10b5-1 |
| Jun 12, 2026 SForm 4 → | Jun 16, 4:42 pm EDT | Roy D. BaynesDirector | 4,500 | $50.00 | $225,000 | 41,500 | −9.78% | 10b5-1 |
| Jun 12, 2026 MForm 4 → | Jun 16, 4:42 pm EDT | Roy D. BaynesDirector | 4,500 | $21.38 | $96,210 | 46,000 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 MForm 4 → | Sep 17, 9:35 pm EDT | William E. RoteChief Research Officer | 191,500 | — | — | 0 | — | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:35 pm EDT | Peter HeermaEVP, CHIEF COMMERCIAL OFFICER | 258,189 | — | — | 44,837 | — | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:33 pm EDT | Jula InrigEVP, Head of R&D & CMO | 32,395 | — | — | 43,605 | — | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:32 pm EDT | Elizabeth E ReedChief Legal Officer and GC | 37,500 | — | — | 0 | — | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:31 pm EDT | Eric M DubeCHIEF EXECUTIVE OFFICER, Director | 400,000 | — | — | 0 | — | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:30 pm EDT | Christopher R. ClineCHIEF FINANCIAL OFFICER | 20,000 | — | — | 0 | — | 10b5-1 |
| Sep 15, 2026 MForm 4 → | Sep 17, 9:29 pm EDT | Sandra CalvinSVP, CHIEF ACCOUNTING OFFICER | 5,375 | — | — | 17,875 | — | 10b5-1 |
| Sep 10, 2026 MForm 4 → | Sep 11, 4:05 pm EDT | Jeffrey A MecklerDirector | 20,000 | — | — | 0 | — | 10b5-1 |
| Aug 17, 2026 MForm 4 → | Aug 19, 4:05 pm EDT | Gary A LyonsDirector | 10,000 | — | — | 0 | — | 10b5-1 |
| Jun 12, 2026 MForm 4 → | Jun 16, 4:46 pm EDT | Timothy CoughlinDirector | 10,000 | — | — | 0 | — | 10b5-1 |
| Jun 12, 2026 MForm 4 → | Jun 16, 4:42 pm EDT | Roy D. BaynesDirector | 4,500 | — | — | 0 | — | 10b5-1 |